Akebia to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--()--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will be presenting at the following investor conferences:

  • The 15th Annual Morgan Stanley Global Healthcare Conference on Monday, September 11, 2017 at 9:55 a.m. Eastern Time. The conference is being held at the Grand Hyatt New York.
  • The 19th Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 12, 2017 at 8:45 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.
  • The Cantor Fitzgerald 2017 Global Healthcare Conference on Tuesday, September 26, 2017 at 2:50 p.m. Eastern Time. The conference is being held at the InterContinental New York Barclay Hotel.

A live audio webcast of the presentations will be available on the company's website at http://ir.akebia.com/events.cfm. Archived presentations will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia's lead product candidate, vadadustat, is an oral, investigational therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. In addition, the Company has initiated the Phase 2 FO2RWARD study of vadadustat in dialysis-dependent chronic kidney disease patients who are hyporesponsive to erythropoiesis-stimulating agents (ESAs), and expects to commence the Phase 3 TRILO2GY study to further evaluate a three-times-weekly dosing regimen for vadadustat. For more information, please visit our website at www.akebia.com.

Contacts

Akebia:
Theresa McNeely, 617-844-6113
SVP, Corporate Communications and Investor Relations
tmcneely@akebia.com

Contacts

Akebia:
Theresa McNeely, 617-844-6113
SVP, Corporate Communications and Investor Relations
tmcneely@akebia.com